Aimmune Therapeutics (AIMT) Lowered to “Sell” at Zacks Investment Research

Zacks Investment Research downgraded shares of Aimmune Therapeutics (NASDAQ:AIMT) from a hold rating to a sell rating in a research note released on Monday.

According to Zacks, “Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company’s characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California. “

AIMT has been the subject of a number of other reports. Piper Jaffray Companies set a $38.00 price target on shares of Aimmune Therapeutics and gave the stock a buy rating in a research note on Saturday, October 21st. Wedbush reissued an outperform rating and issued a $70.00 price target on shares of Aimmune Therapeutics in a research note on Friday, December 1st. BidaskClub downgraded shares of Aimmune Therapeutics from a buy rating to a hold rating in a research note on Thursday, January 4th. Roth Capital started coverage on shares of Aimmune Therapeutics in a research note on Monday, November 20th. They issued a buy rating and a $60.00 price target for the company. Finally, ValuEngine downgraded shares of Aimmune Therapeutics from a hold rating to a sell rating in a research note on Friday, December 1st. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the stock. Aimmune Therapeutics has an average rating of Hold and an average target price of $55.43.

Aimmune Therapeutics (NASDAQ:AIMT) traded down $0.35 during mid-day trading on Monday, reaching $38.65. 357,000 shares of the company were exchanged, compared to its average volume of 394,862. Aimmune Therapeutics has a 12 month low of $15.97 and a 12 month high of $40.00. The company has a market capitalization of $2,010.00 and a P/E ratio of -16.52.

Aimmune Therapeutics (NASDAQ:AIMT) last released its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.72) by $0.09. equities research analysts anticipate that Aimmune Therapeutics will post -2.51 EPS for the current year.

In other Aimmune Therapeutics news, insider Susan E. Barrowcliffe sold 75,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $37.14, for a total transaction of $2,785,500.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Stephen George Dilly sold 1,154 shares of the firm’s stock in a transaction that occurred on Monday, October 16th. The shares were sold at an average price of $26.24, for a total transaction of $30,280.96. The disclosure for this sale can be found here. Insiders have sold 137,946 shares of company stock valued at $4,991,189 in the last ninety days. Insiders own 17.59% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the business. SG Americas Securities LLC increased its stake in shares of Aimmune Therapeutics by 10.1% during the second quarter. SG Americas Securities LLC now owns 5,451 shares of the biotechnology company’s stock valued at $112,000 after purchasing an additional 499 shares in the last quarter. Legal & General Group Plc increased its stake in shares of Aimmune Therapeutics by 26.6% during the second quarter. Legal & General Group Plc now owns 7,776 shares of the biotechnology company’s stock valued at $160,000 after purchasing an additional 1,634 shares in the last quarter. American International Group Inc. increased its stake in shares of Aimmune Therapeutics by 8.1% during the third quarter. American International Group Inc. now owns 23,591 shares of the biotechnology company’s stock valued at $585,000 after purchasing an additional 1,764 shares in the last quarter. Wells Fargo & Company MN increased its position in shares of Aimmune Therapeutics by 3.4% during the third quarter. Wells Fargo & Company MN now owns 61,266 shares of the biotechnology company’s stock valued at $1,519,000 after acquiring an additional 2,025 shares in the last quarter. Finally, Daiwa SB Investments Ltd. increased its position in shares of Aimmune Therapeutics by 44.5% during the fourth quarter. Daiwa SB Investments Ltd. now owns 7,290 shares of the biotechnology company’s stock valued at $276,000 after acquiring an additional 2,245 shares in the last quarter. 73.34% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This article was first posted by Markets Daily and is the sole property of of Markets Daily. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.themarketsdaily.com/2018/01/12/aimmune-therapeutics-aimt-lowered-to-sell-at-zacks-investment-research.html.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Get a free copy of the Zacks research report on Aimmune Therapeutics (AIMT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply